Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 9/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.56 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6502514 | 0.98 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2HTR6NOS3 | |
| SCHEMBL5829152 | 0.85 | SLC6A2 (0.61) | SLC6A4SLC6A3SLC6A2HTR6NOS3 | |
| SCHEMBL5829819 | 0.85 | SLC6A2 (0.61) | SLC6A4SLC6A3SLC6A2HTR6NOS3 | |
| SCHEMBL7806031 | 0.78 | SLC6A4 (0.80) | SLC6A4SLC6A3SLC6A2HTR6 | |
| SCHEMBL7809824 | 0.76 | SLC6A3 (0.60) | SLC6A4SLC6A3SLC6A2HTR6 | |
| SCHEMBL1335541 | 0.75 | SLC6A4 (0.58) | SLC6A4SLC6A3SLC6A2HTR6 | |
| SCHEMBL1021888 | 0.75 | SLC6A2 (0.58) | SLC6A4SLC6A3SLC6A2HTR6CHRM1 | |
| SCHEMBL1334086 | 0.74 | SLC6A2 (0.40) | SLC6A4SLC6A3SLC6A2CHRM2CHRM4 | |
| Hydrochloric Acid SCHEMBL1023293 | 0.74 | SLC6A2 (0.57) | SLC6A4SLC6A3SLC6A2HTR6 | |
| SCHEMBL6490803 | 0.73 | SLC6A2 (0.54) | SLC6A4SLC6A3SLC6A2HTR6NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0984965-B1 | 8-AZABICYCLO(3,2,1)OCT-2-ENE AND OCTANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACH RECEPTORS | NEUROSEARCH AS (DK) | 2004-05-19 | — | — | EP | claimed |
| US-20040019207-A1 | Amines such as 8-Benzyl-3-(3-pyridyl)-8-azabicyclo(3.2.1) oct-2-ene, that bind to nicotinic acetocholine receptors, used for prophylaxis of nervous system disorders, as analgesis, antiinflammatory agents and drug abuse | NEUROSEARCH A/S | 2004-01-29 | — | — | US | claimed |
| US-6645977-B1 | Amines such as 8-Methyl-3-(3-pyridyl)-8-azabicyclo(3.2.1)-oct-2-ene, administered to humans or animals for prophylaxis of drug abuse or drug dependence | NEUROSEARCH A/S (DK) | 2003-11-11 | — | — | US | claimed |
| EP-0984965-A1 | 8-AZABICYCLO(3,2,1)OCT-2-ENE AND OCTANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACH RECEPTORS | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | claimed |
| WO-1998054181-A1 | 8-AZABICYCLO(3,2,1)OCT-2-ENE AND OCTANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACH RECEPTORS | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | claimed |
| US-6964972-B2 | 8-Azabicyclo(3,2,1)oct-2 ene and octane derivatives as cholinergic ligands at nicotinic ACh receptors | NEUROSEARCH A/S (DK) | 2005-11-15 | — | — | US | disclosed |
| EP-0984965-B1 | 8-AZABICYCLO(3,2,1)OCT-2-ENE AND OCTANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACH RECEPTORS | NEUROSEARCH AS (DK) | 2004-05-19 | — | — | EP | disclosed |
| US-20040019207-A1 | Amines such as 8-Benzyl-3-(3-pyridyl)-8-azabicyclo(3.2.1) oct-2-ene, that bind to nicotinic acetocholine receptors, used for prophylaxis of nervous system disorders, as analgesis, antiinflammatory agents and drug abuse | NEUROSEARCH A/S | 2004-01-29 | — | — | US | disclosed |
| US-6645977-B1 | Amines such as 8-Methyl-3-(3-pyridyl)-8-azabicyclo(3.2.1)-oct-2-ene, administered to humans or animals for prophylaxis of drug abuse or drug dependence | NEUROSEARCH A/S (DK) | 2003-11-11 | — | — | US | disclosed |
| EP-0984965-A1 | 8-AZABICYCLO(3,2,1)OCT-2-ENE AND OCTANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACH RECEPTORS | NEUROSEARCH A/S (DK) | 2000-03-15 | — | — | EP | disclosed |
| WO-1998054181-A1 | 8-AZABICYCLO(3,2,1)OCT-2-ENE AND OCTANE DERIVATIVES AS CHOLINERGIC LIGANDS AT NICOTINIC ACH RECEPTORS | NEUROSEARCH A/S (DK) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019207-A1 | Amines such as 8-Benzyl-3-(3-pyridyl)-8-azabicyclo(3.2.1) oct-2-ene, that bind to nicotinic acetocholine receptors, used for prophylaxis of nervous system disorders, as analgesis, antiinflammatory agents and drug abuse | OPRL1, OPRK1, OPRM1 | SLC6A4 1051/4885SLC6A3 306/4885SLC6A2 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.